Artificial Pancreas
Artificial Pancreas
Artificial Pancreas
Artificial Pancreas
Based on glucose regulatory mechanisms known to date, their impairment in the diabetic state,
and fundamental principles of control theory, some corrections to the present course of research
are proposed to facilitate the removal of this barrier. A greater emphasis on model predictive
controllers or controllers that exploit a mathematical representation, or model, of the patient's
own physiology is proposed. Whole-body physiologically based pharmacokinetics–
pharmacodynamics-type models hold the best odds for enabling a successful closed-loop AP.
However, two major improvements to the diabetes modeling state of the art are required to make
them practical for daily care: integrating hypothalamus–pituitary–adrenal axis and
gastrointestinal tract submodels. Although there are simple representations of these in current
existence, large concerted efforts between experimentalists and modelers will be required to
enhance their accuracy. Finally, changes in hardware that complements controller performance
are suggested. For instance, the development of dual control inputs of insulin and glucagon could
relax tolerances on controller accuracy.
Introduction
A biological cure, which would require either regeneration or transplantation of normal β cells with
long-term success. In the normal pancreas, a significant variety of hormonal, substrate, and neuronal
signals are continuously transduced (sensed), and the appropriate responses in the form of insulin,
amylin, glucagon, and somatostatin are continuously secreted. In the current approach, the AP proposes
to mimic those functions by linking a glucose sensor to an insulin pump via a computer control
algorithm.1,2 The goal is to obtain a safe, effective, and affordable device that operates continuously by
mimicking the pancreas, requiring minimal patient or professional intervention.
NIH: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769707/